Cholangiocarcinoma
In a phase 2 clinical trial, 2 different combinations were studied and compared for use as the first treatments given to patients with cholangiocarcinoma (CCA). Read More ›
Genetic alterations in the FGFR pathway are emerging as promising therapeutic targets in patients with cholangiocarcinoma (CCA). A retrospective chart review (or a medical record review) was performed in patients with CCA who were found to have an FGFR mutation during molecular profiling of the tumor as part of routine care for CCA. Read More ›
By Wayne Kuznar
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker. Read More ›
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion. Read More ›
An Interview with Stacie Lindsey, President, and Melinda Bachini, Advocacy Coordinator, Cholangiocarcinoma Foundation Read More ›
View this slideshow to learn important facts about Gallbladder and bile duct cancer, including statistics, causes and symptoms. Read More ›
The following section features a selection of patient stories submitted to the 2015 Hero of Hope™ Patient Award. These stories illustrate the range of extraordinary patient profiles submitted by patients, family members, friends, and healthcare providers. Read More ›